Comment: Breast-feeding during maternal use of azathioprine [1]

Annals of Pharmacotherapy

Volumn 41, Issue 4, 2007, Pages 719-720

  Gardiner, Sharon J ^a   Gearry, Richard B ^b   Roberts, Rebecca L ^a   Zhang, Mei ^a   Barclay, Murray L ^c   Begg, Evan J ^c  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b MONASH UNIVERSITY   (Australia)

^c CHRISTCHURCH HOSPITAL   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; MERCAPTOPURINE;

ABSENCE OF SIDE EFFECTS; BREAST FEEDING; DRUG CONTRAINDICATION; DRUG MILK LEVEL; DRUG SAFETY; DRUG USE; HUMAN; LETTER; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS;

6-MERCAPTOPURINE; AZATHIOPRINE; BREAST FEEDING; FEMALE; GUANINE NUCLEOTIDES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFANT; METHYLTRANSFERASES; MILK, HUMAN;

EID: 34247277556     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1H152a     Document Type: Letter

References (5)

1. Briggs GG, Freeman RK, Yaffe SJ. Drugs in pregnancy and lactation. 7th ed. Philadelphia: Lippincott Williams & Wilkins, 2005.
2. Moretti ME, Verjee Z, Ito S, Koren G. Breast-feeding during maternal use of azathioprine. Ann Pharmacother 2006;40:2269-72. Epub 28 Nov 2006. DOI 10.1345/aph.1H152
3. Tiede I, Fritz G, Strand S, et al. CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. J Clin Invest 2003;111:1133-45.
4. Gardiner SJ, Begg EJ. Pharmacogenetics, drug metabolizing-enzymes, and clinical practice. Pharmacol Rev 2006;58:521-90.
5. Gardiner SJ, Gearry RB, Roberts RL, Zhang M, Barclay ML, Begg EJ. Exposure to thiopurine drugs through breast milk is low based on metabolite concentrations in mother-infant pairs. Br J Clin Pharmacol 2006; 62:453-6.